Bank of New York Mellon’s Protalix BioTherapeutics PLX Stock Holding History

Bank of New York Mellon’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$543K	Buy	232,992 +13,685	+6%	+$29K	﹤0.01%	3706
2026 Q1	$476K	Buy	219,307 +8,440	+4%	+$20.9K	﹤0.01%	3634
2025 Q4	$380K	Buy	210,867 +72,319	+52%	+$148K	﹤0.01%	3741
2025 Q3	$308K	Buy	138,548 +4,261	+3%	+$6.94K	﹤0.01%	3851
2025 Q2	$199K	Buy	+134,287	New	+$275K	﹤0.01%	3990
2024 Q2	–	Sell	-173,206	Closed	-$218K	–	4230
2024 Q1	$218K	Sell	173,206 -5,289	-3%	-$7.9K	﹤0.01%	3905
2023 Q4	$318K	Buy	178,495 +12,815	+8%	+$19.9K	﹤0.01%	3772
2023 Q3	$275K	Buy	165,680 +18,760	+13%	+$33.7K	﹤0.01%	3841
2023 Q2	$294K	Buy	+146,920	New	+$350K	﹤0.01%	3837
2018 Q1	–	Sell	-1,162	Closed	-$8K	–	4392
2017 Q4	$8K	Buy	+1,162	New	+$7.84K	﹤0.01%	4339
2015 Q1	–	Sell	-1,986	Closed	-$36K	–	4271
2014 Q4	$36K	Buy	+1,986	New	+$42.7K	﹤0.01%	4173

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

MSFS

Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Bank of New York Mellon's PLX Position: Q2 2026 in Review

Bank of New York Mellon increased its Protalix BioTherapeutics (PLX) stake by 6.2% in Q2 2026, buying an estimated $29K and bringing the position to 232,992 shares worth $543K. The position accounts for ﹤0.01% of the portfolio, ranked #3706.

Bank of New York Mellon first reported a position in PLX in Q4 2014 and has held it in 11 quarters since. 39 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Bank of New York Mellon held 232,992 shares of Protalix BioTherapeutics worth $543K as of Q2 2026.
Bank of New York Mellon bought 13,685 Protalix BioTherapeutics shares in Q2 2026, an estimated $29K.
Protalix BioTherapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3706 holding.
Bank of New York Mellon first reported a position in Protalix BioTherapeutics in Q4 2014 and has held it in 11 quarters since.
39 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.